Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Total Assets
Apontis Pharma AG
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Total Assets
€57.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Total Assets
$293.5m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Total Assets
€110.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Total Assets
€51.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Total Assets
€2.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Total Assets
€131.3m
|
CAGR 3-Years
74%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Total Assets?
Total Assets
57.5m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Total Assets amounts to 57.5m EUR.
What is Apontis Pharma AG's Total Assets growth rate?
Total Assets CAGR 3Y
25%
Over the last year, the Total Assets growth was -4%. The average annual Total Assets growth rates for Apontis Pharma AG have been 25% over the past three years .
You don't have any saved screeners yet